Back | Next |
home / stock / moc / moc message board
Subject | By | Source | When |
---|---|---|---|
Very weird. That $5.73 high was shortly | hweb2 | investorshub | 06/06/2016 8:44:39 PM |
Weird day today. High about 5.72 then | cj 13 | investorshub | 06/06/2016 8:37:45 PM |
Low float, 3800 employees, beat out over 80 | cj 13 | investorshub | 06/06/2016 2:56:58 PM |
Looked @ recent 10-Q. > growing revenues. They | crudeoil24 | investorshub | 06/06/2016 2:03:59 PM |
$MOC's a gamer thar now! | swampboots | investorshub | 06/06/2016 1:41:20 PM |
Its a boilerplate sugar daddy, out of draw | swampboots | investorshub | 06/06/2016 1:20:45 PM |
She's moving, on 5K vol. in PM ...Contract | crudeoil24 | investorshub | 06/06/2016 1:07:54 PM |
News but hard to reach. | swampboots | investorshub | 06/06/2016 12:39:41 PM |
What is it? | hi_flyer | investorshub | 01/10/2016 12:26:17 PM |
Yep | otcbloodhound | investorshub | 01/06/2015 3:10:09 PM |
5M > loowww floater! | crudeoil24 | investorshub | 01/06/2015 2:58:11 PM |
GREAT NEWS OUT TODAY. | otcbloodhound | investorshub | 01/06/2015 2:50:24 PM |
Tis' an investment imo. | Penny Roger$ | investorshub | 09/20/2014 12:43:09 AM |
So far I have been wrong | provest | investorshub | 09/20/2014 12:29:07 AM |
I agree | Penny Roger$ | investorshub | 09/09/2014 11:56:42 AM |
MOC I think they pull a$ RADA/$GIGA here | provest | investorshub | 09/09/2014 1:35:01 AM |
Revenue/200sma play here big gains coming | ~S.B.A.~ | investorshub | 11/06/2013 12:55:43 PM |
~ $MOC ~ Earnings posted, pending or coming | Penny Roger$ | investorshub | 02/06/2012 10:33:38 AM |
The number of outstanding shares of the registrants | Soapy Bubbles | investorshub | 03/02/2011 2:50:51 AM |
images.investorshub.advfn.com/images/uploads/2011/3/1/morgjMOC.png | Soapy Bubbles | investorshub | 03/02/2011 2:49:06 AM |
News, Short Squeeze, Breakout and More Instantly...
Command Security Corporation Company Name:
MOC Stock Symbol:
NYSE Market:
OATD-01 is a first-in-class chitotriosidase 1 (CHIT1) inhibitor with the potential to modify the course of disease in sarcoidosis and other interstitial lung diseases. Obtaining regulatory approvals in Denmark, France, Greece, Germany, and Norway enables the conduct of the Phase II clinic...
Initiation of Phase II clinical trial of OATD-01 (KITE) for the treatment of pulmonary sarcoidosis following approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). World's first administration of a chitotriosidase 1...
- OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the phase II clinical trial (KITE study), patients will take a daily oral dose of 25 mg OATD-01 or...